5 Horizons Capital

Too many groundbreaking therapies never reach clinical trials—not because they don’t work, but because they lack the right funding, strategic execution, and regulatory guidance. At 5 Horizons, we’re changing that. Funding. Strategy. Execution. Accelerated. We provide early-stage biotech companies with the capital, expertise, and partnerships needed to bridge the gap between discovery and clinical success. Unlike traditional investors, we go beyond funding. We partner with biotech leaders to de-risk clinical trials, optimize financial strategy, and provide hands-on execution support, ensuring your therapy advances with confidence. We partner with select biotech startups that meet the following criteria: ▪ Within 18 months of entering clinical trials, with preclinical work completed or nearing completion. ▪ Haven’t chosen a CRO and are open to discussions with Novotech. ▪ Have at least 50% of the required funding secured, including 5 Horizons’ contribution and a lead anchor investor.